Clinical Trial Update: Multi-centre, Open-label, First-in-man Study With Mucopad HA [NA]

View source ↗

Summary

A multi-centre, open-label first-in-man study of Mucopad HA for oral mucositis has been completed. The sponsor is Contipro Pharma a.s.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oral Mucositis

Drugs mentioned

• Mucopad HA

Snippet

Sponsor: Contipro Pharma a.s. | Conditions: Oral Mucositis | NA | Status: COMPLETED